Interim Report, January-June 2013 January-June 2013

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 2, 2013 at 2:15 AM

Interim Report, January-June 2013

January-June 2013 · Group net sales reached SEK 6,478 million (6,758), corresponding to organic growth[1] of 1% compared to previous year. · EBITDA amounted to SEK 1,845 million (2,180), corresponding to a 28.5% margin (32.3). · Operating profit totaled SEK 765 million (1,109). · Profit after tax amounted to SEK 400 million (651). · Earnings per share reached SEK 1.34 (2.19). · Cash earnings per share amounted to SEK 3.81 (4.45). Second quarter 2013 · Group net sales reached SEK 3,279 million (3,383), corresponding to organic growth[1] of 2% compared to previous year. · EBITDA amounted to SEK 922 million (1,027), corresponding to a 28.1% margin (30.4). · Operating profit totaled SEK 381 million (489). · Profit after tax amounted to SEK 192 million (283). · Earnings per share reached SEK 0.64 (0.95). · Cash earnings per share amounted to SEK 2.04 (2.52). CEO statement Our focus on growth is beginning to show results. Organic growth in the second quarter stood at 2% as sales of Dymista were able to help compensate for generic competition on some older products in the US market. Our US operation showed organic growth of 4%. The Dymista launch is on schedule, and we continue to gradually roll out the product in new European markets. Growth in Emerging Markets is good, while OTC products declined in the second quarter. This was primarily due to lower sales of certain OTC products in the Nordics as well as Betadine in southern Europe. As previously announced, we are prioritizing OTC efforts internationally, and we see good growth for these products and markets. These efforts to increase growth will have a negative effect on profitability in the short term but should help increase the company’s profitability in the long -term. As far as the outlook for the remainder of 2013, I stand firm on the assessment that we will achieve organic growth of 3-5% for full year 2013. This challenge is in line with our plans and means that we are counting on higher growth in the second half of the year than we have had in the first half. Most of this increase is expected to occur in the fourth quarter. This growth will be driven by Dymista and Emerging Markets. Anders Lönner Group president and CEO 1) Organic growth is defined as sales growth adjusted for currency effects, acquisitions, disposed operations, and revenues from the cooperation agreement with Valeant. Webcasted presentation of the report on August 2 at 10:30 AM The presentation can be reached at www.meda.se/financial -information (http://www.meda.se/sv/finansiell-information). A recorded version will also be available until the next interim report is presented. For further inquiries, please contact: Anders Larnholt, VP Corporate Development and Investor Relations, anders.larnholt@meda.se, 46 709?458 878. Paula Treutiger, Investor Relations, paula.treutiger@meda.se, 46 733-666 599. The company’s auditors did review this interim report. FORWARD-LOOKING STATEMENT This report is not an offer to sell or a solicitation to buy shares in Meda. This report also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward -looking statements can be identified by the fact that they do not relate only to historical or current facts and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe”, or other words of similar meaning. These forward-looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development, and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses, or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. Meda does not intend or undertake to update any such forward-looking statements.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...